150 related articles for article (PubMed ID: 22642767)
1. A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma.
Shinohara N; Nonomura K; Abe T; Maruyama S; Kamai T; Takahashi M; Tatsugami K; Yokoi S; Deguchi T; Kanayama H; Oba K; Naito S
Cancer Sci; 2012 Sep; 103(9):1695-700. PubMed ID: 22642767
[TBL] [Abstract][Full Text] [Related]
2. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era?
Shinohara N; Abe T; Mochizuki T; Kashiwagi A; Kanagawa K; Maruyama S; Sazawa A; Oba K; Nonomura K
Urol Oncol; 2013 Oct; 31(7):1276-82. PubMed ID: 21956045
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy.
Shinohara N; Obara W; Tatsugami K; Naito S; Kamba T; Takahashi M; Murai S; Abe T; Oba K; Naito S
Cancer Sci; 2015 May; 106(5):618-26. PubMed ID: 25711777
[TBL] [Abstract][Full Text] [Related]
4. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.
Chrom P; Zolnierek J; Bodnar L; Stec R; Szczylik C
Int J Clin Oncol; 2019 May; 24(5):526-532. PubMed ID: 30604160
[TBL] [Abstract][Full Text] [Related]
5. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.
Kamba T; Yamasaki T; Teramukai S; Shibasaki N; Arakaki R; Sakamoto H; Matsui Y; Okubo K; Yoshimura K; Ogawa O
Int J Clin Oncol; 2014; 19(3):505-15. PubMed ID: 23813043
[TBL] [Abstract][Full Text] [Related]
6. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
Motzer RJ; Mazumdar M; Bacik J; Berg W; Amsterdam A; Ferrara J
J Clin Oncol; 1999 Aug; 17(8):2530-40. PubMed ID: 10561319
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients.
Naito S; Kinoshita H; Kondo T; Shinohara N; Kasahara T; Saito K; Takayama T; Masumori N; Takahashi W; Takahashi M; Terachi T; Ozono S; Naito S; Tomita Y
Urology; 2013 Oct; 82(4):846-51. PubMed ID: 24074981
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Heng DY; Xie W; Regan MM; Warren MA; Golshayan AR; Sahi C; Eigl BJ; Ruether JD; Cheng T; North S; Venner P; Knox JJ; Chi KN; Kollmannsberger C; McDermott DF; Oh WK; Atkins MB; Bukowski RM; Rini BI; Choueiri TK
J Clin Oncol; 2009 Dec; 27(34):5794-9. PubMed ID: 19826129
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil number after interferon-alfa treatment is an independent predictive marker of overall survival in metastatic renal cell carcinoma.
Azuma T; Matayoshi Y; Nagase Y; Oshi M
Clin Genitourin Cancer; 2012 Sep; 10(3):180-4. PubMed ID: 22608529
[TBL] [Abstract][Full Text] [Related]
10. Metastatic renal carcinoma comprehensive prognostic system.
Atzpodien J; Royston P; Wandert T; Reitz M;
Br J Cancer; 2003 Feb; 88(3):348-53. PubMed ID: 12569375
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
Motzer RJ; Bacik J; Murphy BA; Russo P; Mazumdar M
J Clin Oncol; 2002 Jan; 20(1):289-96. PubMed ID: 11773181
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Ku JH
Tumori; 2007; 93(1):68-74. PubMed ID: 17455874
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.
Kawano Y; Takahashi W; Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S
Cancer Sci; 2016 Jul; 107(7):1013-7. PubMed ID: 27089226
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
[TBL] [Abstract][Full Text] [Related]
15. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
[TBL] [Abstract][Full Text] [Related]
16. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
17. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A
World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581
[TBL] [Abstract][Full Text] [Related]
18. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
Heng DY; Xie W; Regan MM; Harshman LC; Bjarnason GA; Vaishampayan UN; Mackenzie M; Wood L; Donskov F; Tan MH; Rha SY; Agarwal N; Kollmannsberger C; Rini BI; Choueiri TK
Lancet Oncol; 2013 Feb; 14(2):141-8. PubMed ID: 23312463
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma.
Zheng W; Zhu W; Yu S; Li K; Ding Y; Wu Q; Tang Q; Zhao Q; Lu C; Guo C
BMC Cancer; 2020 Nov; 20(1):1066. PubMed ID: 33148204
[TBL] [Abstract][Full Text] [Related]
20. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
Jeon SH; Chang SG; Kim JI
Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
